Trial · NCT04602000
Results by group167
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 167
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) | CT-P59 40 mg/kg Group (Part 1) | 4 | Participants | ||
| Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) | CT-P59 80 mg/kg Group (Part 1) | 5 | Participants | ||
| Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) | Placebo Group (Part 1) | 9 | Participants | ||
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 2 | 0 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 2 | 1 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | Placebo Group (Part 1) | Day 2 | 0 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 3 | 4 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 3 | 4 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | Placebo Group (Part 1) | Day 3 | 3 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 4 | 2 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 4 | 6 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | Placebo Group (Part 1) | Day 4 | 4 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 5 | 7 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 5 | 3 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | Placebo Group (Part 1) | Day 5 | 2 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 6 | 5 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 6 | 5 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | Placebo Group (Part 1) | Day 6 | 4 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 40 mg/kg Group (Part 1) | Day 7 | 8 | Participants | |
| Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) | CT-P59 80 mg/kg Group (Part 1) | Day 7 | 12 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04602000/results